title: [Therapeuric aspects of NAFLD. A literature review].
abstract: The prevalence of non-alcoholic steatohepatitis has increased in the last years, paralleling the increasing incidence of overweight and obesity in the general population and related comorbidities. It is expected that in near future, non-alcoholic steatohepatitis will be responsible for a large number of subjects with chronic liver disease due to fatty liver Because of this, treatment options for fatty liver are necessary. To date, the cornerstone of treatment is based in weight reduction, with diet and increased physical activity, although reports indicating that insulin sensitizers and medications that reduce oxidative stress may hold promise for the treatment of this condition. This article reviews the most important aspects of treatment of non-alcoholic steatohepatitis.
authors.affiliation: Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán.
authors.forename: Norberto C Chávez
authors.initials: NC
authors.lastname: Tapia
authors.forename: Félix I Téllez
authors.initials: FI
authors.lastname: Avila
authors.forename: Jorge García
authors.initials: JG
authors.lastname: Leiva
authors.forename: Martha H Uribe
authors.initials: MH
authors.lastname: Ramos
authors.forename: Juan Francisco Sánchez
authors.initials: JF
authors.lastname: Avila
authors.forename: Misael
authors.initials: M
authors.lastname: Uribe
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D005234:Fatty Liver / Q000178:diet therapy / Q000453:epidemiology / Q000473:pathology / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D009765:Obesity / Q000150:complications; D009626:Terminology as Topic; D045162:Thiazolidinediones / Q000627:therapeutic use; D015431:Weight Loss
chemical_list: D000975:Antioxidants; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones